Exploiting High-Throughput Cell Line Drug Screening Studies to Identify Candidate Therapeutic Agents in Head and Neck Cancer by Nichols, Anthony C et al.
Western University
Scholarship@Western
Oncology Publications Oncology Department
11-2014
Exploiting High-Throughput Cell Line Drug
Screening Studies to Identify Candidate
Therapeutic Agents in Head and Neck Cancer
Anthony C Nichols
Western University, anthony.nichols@lhsc.on.ca
Morgan Black
John Yoo
Nicole Pinto
Andrew Fernandes
See next page for additional authors
Follow this and additional works at: https://ir.lib.uwo.ca/oncpub
Part of the Oncology Commons
Citation of this paper:
Nichols, Anthony C; Black, Morgan; Yoo, John; Pinto, Nicole; Fernandes, Andrew; Haibe-Kains, Benjamin; Boutros, Paul C; and
Barrett, John W, "Exploiting High-Throughput Cell Line Drug Screening Studies to Identify Candidate Therapeutic Agents in Head
and Neck Cancer" (2014). Oncology Publications. 81.
https://ir.lib.uwo.ca/oncpub/81
Authors
Anthony C Nichols, Morgan Black, John Yoo, Nicole Pinto, Andrew Fernandes, Benjamin Haibe-Kains, Paul
C Boutros, and John W Barrett
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/oncpub/81
RESEARCH ARTICLE Open Access
Exploiting high-throughput cell line drug screening
studies to identify candidate therapeutic agents in
head and neck cancer
Anthony C Nichols1*, Morgan Black1, John Yoo1, Nicole Pinto1, Andrew Fernandes2, Benjamin Haibe-Kains3,
Paul C Boutros4,5,6 and John W Barrett1
Abstract
Background: There is an urgent need for better therapeutics in head and neck squamous cell cancer (HNSCC)
to improve survival and decrease treatment morbidity. Recent advances in high-throughput drug screening
techniques and next-generation sequencing have identified new therapeutic targets in other cancer types, but an
HNSCC-specific study has not yet been carried out. We have exploited data from two large-scale cell line projects
to clearly describe the mutational and copy number status of HNSCC cell lines and identify candidate drugs with
elevated efficacy in HNSCC.
Methods: The genetic landscape of 42 HNSCC cell lines including mutational and copy number data from studies
by Garnett et al., and Barretina et al., were analyzed. Data from Garnett et al. was interrogated for relationships
between HNSCC cells versus the entire cell line pool using one- and two-way analyses of variance (ANOVAs).
As only seven HNSCC cell lines were tested with drugs by Barretina et al., a similar analysis was not carried out.
Results: Recurrent mutations in human papillomavirus (HPV)-negative patient tumors were confirmed in HNSCC
cell lines, however additional, recurrent, cell line-specific mutations were identified. Four drugs, Bosutinib, Docetaxel,
BIBW2992, and Gefitinib, were found via multiple-test corrected ANOVA to have lower IC50 values, suggesting higher
drug sensitivity, in HNSCC lines versus non-HNSCC lines. Furthermore, the PI3K inhibitor AZD6482 demonstrated
significantly higher activity (as measured by the IC50) in HNSCC cell lines harbouring PIK3CA mutations versus those
that did not.
Conclusion: HNSCC-specific reanalysis of large-scale drug screening studies has identified candidate drugs that
may be of therapeutic benefit and provided insights into strategies to target PIK3CA mutant tumors. PIK3CA
mutations may represent a predictive biomarker for response to PI3K inhibitors. A large-scale study focused on
HNSCC cell lines and including HPV-positive lines is necessary and has the potential to accelerate the development
of improved therapeutics for patients suffering with head and neck cancer. This strategy can potentially be used as
a template for drug discovery in any cancer type.
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Background
Despite advances in multi-modal treatment of head and
neck squamous cell carcinoma (HNSCC), mortality rates
for advance disease remain high [1]. Thus there is an ur-
gent need to identify novel chemicals with high activity
in this disease. As with other tumor types, however, the
time- and resource-intensive, multi-step clinical trial
process remains a tremendous barrier to rapid drug de-
velopment. Moreover, only specific molecular subtypes
of tumors may respond to any given target agent [2],
thereby decreasing the number of patients eligible for a
particular study.
Targeted therapy has become an important method in
personalizing treatment for cancer patients based on the
genetic mutations present in their tumor(s). Such ther-
apies enable the use of drugs to specifically target mole-
cules within the tumor that are responsible for the
malignancy. A search of the literature, as well as clinical
trials that are currently underway in HNSCC, revealed a
variety of agents being investigated that target various
cellular molecules (e.g. epidermal growth factor receptor
[EGFR], members of the phosphatidylinositide 3-kinase
[PI3K] pathway, mammalian target of rapamycin [mTOR],
cyclin-dependent kinases, vascular endothelial growth fac-
tor receptor [VEGFR], retinoblastoma protein [pRB], toll-
like receptors and Aurora kinases) (clinicaltrials.gov).
However, despite the multiple trials, only EGFR tyrosine
kinase inhibitors and EGFR monoclonal antibodies (e.g.
cetuximab) have been approved for clinical use and dem-
onstrate only modest activity in a subset of patients [3].
New strategies are needed not only to identify active mole-
cules, but also to define the target population that is most
likely to benefit from therapy.
Cell lines are imperfect models of cancer: they tend to
be generated from more aggressive, often metastatic tu-
mors, can demonstrate genetic and epigenetic changes
relative to the parent tumors, and lack interactions with
the surrounding stroma and immune system [4-7]. How-
ever, they remain an invaluable discovery tool as they
provide an unlimited source of self-replicating material,
are easily manipulated and can be screened in a cheap
and high-throughput way with large panels of drugs.
Moreover, relationships between drug sensitivity and
tumor genotypes observed in patient samples are also
reflected in cell lines [8].
The advent of next generation sequencing has allowed
complete, affordable and rapid genomic characterization
of both patient samples and of cell lines. In parallel, the
development of high-throughput robotic drug screening
platforms has facilitated the rapid testing of a large num-
ber of drugs. Together these techniques provide the abil-
ity to correlate mutation status, copy number variation
and expression levels with drug response. Two recent,
large-scale studies, involving hundreds of cell lines of
different tissue types [8,9] have confirmed well known
genetic markers of drug response (e.g. response to BRAF
inhibitors in BRAF mutant cell lines) and identified
novel associations such as the marked sensitivity of
Ewing’s sarcoma cells harboring the EWS-FLI1 gene
translocation to poly(ADP-ribose) polymerase (PARP)
inhibitors [8]. However, given the large volume of data
generated, only a limited analysis of the HNSCC cell
lines involved in either study was presented. We endea-
voured to reanalyze the data presented in these studies
to provide a mutational landscape of HNSCC cell lines
and to identify markers of drug sensitivity and resistance
in HNSCC.
Methods
Defining the mutational and copy number landscape of
HNSCC cell lines
The study by the Broad-Novartis group (Barretina et al.)
included 31 HNSCC cell lines (of 947 total), seven of
which were screened with 24 anticancer agents [9]. The
cell lines were characterized by sequencing of ~1500
genes, as well as with array-based copy number variation
(CNV) analysis and using mRNA abundance microar-
rays. A second study, by Garnett and coworkers, evalu-
ated 639 cell lines (22 HNSCC lines) treated with 131
agents and characterized by targeted sequencing of 60
cancer genes, as well as array-based assessment of CNVs
and mRNA abundance [8]. Note that eleven identically
named HNSCC cell lines were common to both studies
yielding a total of 42 uniquely named cell lines when
both studies were combined. We integrated the CNV
and mutational analysis of the most commonly altered
genes from the two studies into Figures 1 and 2 and cor-
related them with the changes reported from patient
samples by Stransky et al. [10]. CNV levels from Garnett
et al., were simply reported as 0 (deletion), between 0
and 8 (copy-number neutral), and greater than 8 (ampli-
fication). Barretina et al. reported CNVs as continuous
variables, relative to control genes with 0 considered
“non-amplified”. We considered values greater than 2
(reflecting at least 2 extra gene copies) as amplifications
and less than −2 (representing homozygous deletion) as
this appeared to agree with the TCGA data from http://
cbioportal.org and correspond best with the amplifica-
tions and deletions noted in the study by Garnett et al.
(Additional file 1: Table S1).
Identification of biomarkers of chemotherapeutic
sensitivity and resistance in HNSCC cell lines
Due to the small number of HNSCC cell lines that were
treated with drugs in Barretina et al. (7 lines), we re-
stricted drug sensitivity analysis to the data from Garnett
et al. [8]. All statistical analysis was performed with the
R statistical environment, version 2.15.2 (R Foundation
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for Statistical Computing) with the fdrtool package [11] ver-
sion 1.2.10, to control the rate of false discovery due to
multiple testing. We compared the half-maximal inhibitory
concentration (IC50 in μM) for each drug between HNSCC
cell lines and non-HNSCC cell lines via one-way analysis of
variance (ANOVA) as computed through t-tests. Specific-
ally, for each drug i, cell lines were partitioned into two
groups j = {HNSCC, non-HNSCC} as per their cell-line
type. Letting k denote replicate number, the linear model
for each t-test was the standard yijk = μj + εijk, where yijk
represents the observed log2(IC50), μj represents the mean
response of group j, and each εijk represents a realization of
εeN 0; σ2i
 
. To control the false discovery rate, the “local
false discovery rate” (LFDR) was estimated via computed
p-values using Strimmer’s fdrtool [11,12]. The LFDR has
been championed by Efron and others for genomic studies
Figure 2 Genetic landscape of head and neck cancer cell lines based on data from Garnett et al., Nature 2012.
Figure 1 Genetic landscape of head and neck cancer cell lines based on data from Barretina et al., Nature 2012.
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as it is directly interpretable as posterior probability, and
not a “corrected p-value” [13,14]. A LFDR <0.05 was
considered significant and a LFDR <0.1 was considered to
be approaching statistical significance. We then looked for
associations of copy number changes and mutations with
response to drug treatment by two-way ANOVA including
factor interaction, again using the LFDR to control false
discovery rates. Specifically, the linear models used for the
ANOVAs was yijk = μ + αi + βj + γij + εijk where group i =
{copy-number unchanged, copy-number changed}, group
j = {wild-type, mutant}, and k again denotes replicate
number. As per standard ANOVA, αi and βj represent
the mean additive responses of their respective groups,
γij represents any non-additive interaction effect, εijk
represents a realization of ε ~ N(0, σ2), and μ repre-
sents the grand-mean effect. The standard constraints
∑iαi = 0, ∑jβj = 0, and ∑ijγij = 0 were used to ensure that
all parameters of each model were identifiable.
Results
The genetic landscape of HNSCC cell lines is similar to
HPV-negative tumors
The mutational landscape of the 42 HNSCC cell lines,
all of which were HPV-negative [7], demonstrated simi-
larities with primary tumor samples from HPV-negative
patients; including frequent mutations in tumor suppres-
sor genes TP53 (74% of cell-lines [9]; 62% of tumors
[10]) and CDKN2A, and less frequent ones in PTEN,
SMAD4, NOTCH1 and NOTCH2 (Figures 1 and 2).
Other similarities were rare activating mutations in on-
cogenes PIK3CA and HRAS, deletions of CDKN2A and
amplifications of CCND1, epidermal growth factor re-
ceptor (EGFR), MYC and PIK3CA. A complete listing of
mutations identified in HNSCC cell lines in Barretina et al.
is provided in Additional file 2: Table S2. However,
there were multiple, recurrent mutations in genes rarely
or not identified in the patient samples (Additional file 2:
Table S2 and Additional file 3: Table S3). In fact, there
were 22 genes more frequently mutated than TP53, which
was the most commonly mutated gene found in tumor
samples (Additional file 3: Table S3). Most of these muta-
tions were identical in all cell lines, such as two 5′ UTR
mutations observed in neural cell adhesion molecule 1
(NCAM1) (insertion of adenine at position 112832307
(dbSNP ID: rs117108942) and deletion of cytosine at pos-
ition 112832340) in virtually every HNSCC cell line in
Barretina et al. Of note, 11 cell lines with the same name
were characterized in both studies. However, two of these
lines had significant discrepancies in terms of mutations
between the studies (BHY, SCC9) bringing the true iden-
tities of the lines into question (Additional file 1: Table S1).
Personal correspondence with the authors of Barretina
et al. and the methods section of Garnett et al., have con-
firmed that the identification of their cell lines were
confirmed with genotyping. The genotyping results are
not provided in the supplementary data to allow direct
comparison.
Chemicals with high and low activity in HNSCC cell lines
Four chemicals, Docetaxel (anti-mitotic chemotherapy),
Bosutinib (combined SRC/ABL inhibitor), Afatinib (an
EGFR and HER2 inhibitor), and Gefitinib (an EGFR in-
hibitor) were found to have significantly increased activ-
ity in HNSCC cell lines compared with the remainder of
the cell line pool (Table 1, Figure 3). Two drugs, metho-
trexate and PD-173074 (an inhibitor of the fibroblast
growth factor receptor [FGFR] and VEGFR) were found
to have significantly lower activity in HNSCC lines
(Table 1). A complete listing of the associations between
drug response and HNSCC cell line type can be found
in Additional file 4: Table S4.
Of note, there were five identically named cell lines
in both studies that were tested with identical drugs
(Additional file 5: Table S5), four of which had similar
mutational profiles suggesting that they were indeed
identical lines. SCC-9 was excluded due to discrepan-
cies in the mutational profiles reported by Barretina
et al. and Garnett et al. (Additional file 1: Table S1).
We sorted the comparable IC50s into three groups,
representing cell lines that were exquisitely sensitive
(IC50 < 3 μM) to the drug, responders (IC50 3.1-7.9 μM)
and resistant cell lines (IC50 > 8 μM). We found that the
majority were comparable (Additional file 5: Table S5).
Activating PIK3CA mutations are correlated with response
to the PI3K inhibitor, AZD6482
The complete listing of drug sensitivity and gene status
can be found in Additional file 6: Table S6, with the sig-
nificant findings summarized in Table 2. Only mutations
and copy number changes in EGFR, TP53, CDKN2A,
PIK3CA and SMAD4 were present with sufficient fre-
quency (>10%) in the cell lines to allow analysis. It
should be noted that not all cell lines were treated with
every drug and some genetic changes occurred in a very
small number of cell lines, which resulted in exclusion
of analysis of certain drugs with a particular genetic
change. Of the 131 drugs tested, three were PI3K inhibi-
tors including AZD6482, GDC0941, and the combined
mTOR and PI3K inhibitor NVP-BEZ235. We calculated a
robust increase in sensitivity to AZD6482, explainable by
the interaction of PIK3CA mutation status and HNSCC
cell-line type (LFDR <0.023, Figure 1). In addition, an in-
crease in AZD6482 sensitivity was shared by all PIK3CA
mutants (p <0.037, Figure 4A) regardless of cell line type.
No association was observed for the other PI3K inhibitors,
GDC0941 and NVP-BEZ235, and PIK3CA mutation sta-
tus (LFDR ≈ 1). There were too few PIK3CA amplified cell
lines to examine the effect of amplification alone on drug
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response, however when these were pooled with the
PIK3CA mutant lines, no drugs were found to be prefer-
entially active when compared to PIK3CA wild-type cell
lines (Additional file 6: Table S6).
When examining responses to inhibitors of upstream
and downstream members of the PIK3CA pathway, the
FAK inhibitor PF-562271 (upstream) demonstrated a
trend towards selective inhibition of PIK3CA HNSCC
mutant cell lines (LFDR = 0.079, Figure 4B), while no ef-
fect was observed for downstream inhibitors including
three AKT inhibitors (AKT inhibitor VIII, MK-2206,
A-443654) and four mTOR inhibitors (Rapamycin,
Temsirolimus, JW-7-52-1, AZD8055).
There was a trend towards increased sensitivity to
AZD6482 and JNK Inhibitor VIII in cell lines with
EGFR amplifications (LFDR = 0.056, Figure 4C). The
strongest association observed was increased activity
of the retinoid receptor antagonist ATRA in TP53
mutant lines (LFDR = 0.007, Table 2 and Additional
file 6: Table S6).
Discussion
Following decades of active research, only one class of
targeted molecular agents, epidermal growth factor re-
ceptor (EGFR) inhibitors, have been approved for use in
head and neck cancers [15]. Despite a modest survival
benefit when administered concurrently with radiation,
response rates to EGFR inhibitors are low when given
alone (13%) and of limited duration (2–3 months). More
effective drugs are needed in order to improve outcomes
and reduce treatment-induced morbidities for HNSCC
patients.
By pairing next-generation sequencing of cell lines
with high-throughput drug screening techniques, the
impressive studies by Garnett et al. and Barretina et al.
[8,9], confirmed, in multiple tissue types, known associa-
tions of genetic alterations with drug sensitivity and
uncovered a multitude of new ones. Their sequencing
findings were in agreement with preliminary data from
The Cancer Genome Atlas (TCGA) HNSCC study, where
a multitude of potentially druggable targets including
Table 1 Drugs demonstrating significantly increased or decreased activity in HNSCC cell lines compared with non-
HNSCC lines
Drug p* LFDR** Drug response relative to other cell lines Effect (Log2(IC50(μM)) 95% CI (Log2(IC50(μM)))
Bosutinib <0.0001 0.0015 Sensitive −2.74 (−3.67 to −1.82)
Docetaxel <0.0001 0.0161 Sensitive −2.29 (−3.17 to −1.42)
BIBW2992 0.0002 0.0161 Sensitive −3.12 (−4.53 to −1.71)
Gefitinib 0.0003 0.0258 Sensitive −2.18 (−3.24 to −1.12)
PD-173074 0.0002 0.0183 Resistance 0.95 (0.50-1.40)
Methotrexate 0.0005 0.0258 Resistance 1.59 (0.77-2.42)
Legend: * - calculated by one way analysis of variance (ANOVA), LFDR - local false discovery rate, ** - calculated by the Strimmer method, IC50 - half maximal
inhibitory concentration, CI - confidence interval.
Figure 3 Drug activity of HNSCC vs. non-HNSCC (“Other”) cell lines from Garnett et al., Nature 2012. Points represent individual observations,
while boxes show estimates of the respective median, interquartile range, and extrema.
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amplifications (e.g. FGFR1, CCND1, MYC, EGFR), dele-
tions (e.g. PTEN), activating mutations (e.g. PIK3CA) and
fusions (e.g. FGFR3/TACC3) were observed. Despite a
relatively limited number of cell lines, our HNSCC-specific
reanalysis of these studies shows that the spectrum of mu-
tations observed in HNSCC cell lines is similar to that of
primary HNSCC patient samples [10,16]. Overall, muta-
tions in tumor suppressor genes, such as TP53 are frequent,
while activating mutations in oncogenes (PIK3CA, HRAS)
occur at lower frequencies.
As mentioned, our analysis revealed 22 genes that are
more frequently mutated than TP53, which is the most
commonly mutated gene found in patient tumor sam-
ples (Additional file 3: Table S3). This discrepancy may
be partially explained by the fact that mutations in in-
trons and 5′ and 3′ untranslated regions (UTRs) were
reported for the cell lines but not for the patient sam-
ples. In addition, there were multiple, identical muta-
tions noted in cell lines, such the mutations observed in
NCAM1 [9]. Interestingly, NCAM1 is known to signal
through FAK, a direct target of PF-562271, which may
contribute to its observed activity in PIK3CA-mutant
HNSCC cell lines. However, we speculate that the near
identical mutations found in these 22 highly mutated
genes are germ-line variants and/or artifacts of cell line
establishment. This inability to distinguish the cause of
mutation(s) highlights the importance of comparing
tumor sample or cell line DNA, to matched-normal tis-
sue. Moving forward, it is crucial that matched-normal
tissue and blood samples, representing the germ-line
genetic profile are obtained when cell lines are estab-
lished for improved sequencing analyses.
The most obvious directly druggable target in HNSCC
appears to be the PI3K pathway, which was mutated in
8% of the patient samples examined by Stransky et al.
[10]. We noted that activating PIK3CA mutations ap-
peared to be more frequent in three HPV-positive tu-
mors sequenced by Stransky et al., and we confirmed
this finding by sequencing the PIK3CA hotspots in a
larger number of HPV-positive (46) and negative (43)
oropharyngeal HNSCC samples [17]. We found that
PIK3CA mutations occurred in 28% of the HPV-positive
oropharyngeal tumors versus 10% of the HPV-negative
samples, confirming that this is an important therapeutic
target in HNSCC. There is great interest in targeting
PI3K as it is frequently either amplified or mutated in a
large variety of human cancers [18], however the selec-
tion of the best possible drug is critical before moving
forward with clinical studies. Selection of the appropriate
agent is crucial because different drugs, which might tar-
get the same molecule, can display extremely variable
potencies based on a variety of factors including a drug’s
binding site, delivery efficiency, half-life and metabolic
interactions. An additional limitation of our analysis in
terms of drug development progressing to routine
patient care is the low number of drugs tested against
the cell lines. Increasing the number of drugs tested, in-
cluding drugs targeting identical molecules, would help
ensure that potent drugs are identified and cellular tar-
gets further verified in the most appropriate patient
population.
Cell lines are not perfect models of cancer due to their
lack of three-dimensional stromal environment, lack of
interactions with an immune system, and an inability to
test drug delivery issues. Many of these concerns can be
overcome in xenografts and human testing. The utility
of cell line drug screening, given that poor correlation of
drug testing in matched cell lines and patients have vari-
ably been observed [19,20] while patient derived xeno-
grafts appear to preserve nearly all the molecular feature
of the original tumor. Emerging data suggests that while
many cell lines may not recapitulate the molecular land-
scape of primary tumors, selecting cell line models with
comparable genetic profiles will yield more accurate
drug screening results [21-23]. With appropriate cell line
models selected, cell line screening can be a robust,
rapid and inexpensive preliminary screen before pro-
ceeding with more expensive and ethically-challenging
animal and human studies. In our study, only molecules
affecting the PI3K pathway (AZD6482 and PF-562271)
were correlated with selective inhibition of PIK3CA
mutant lines. However, it is somewhat surprising that
AZD6482 was the most tightly correlated with PIK3CA
mutation status as it has approximately an 87-fold higher
affinity for PI3Kβ than PI3Kα [24]. It is noteworthy that
AZD6482 appeared significantly more effective than the
Table 2 Significant associations of mutations and amplifications with drug response in HNSCC cell lines
Drug Gene Comparison p LFDR Mean WT/NA
log2(IC50(μM))
Mut/Amp
log2(IC50(μM))
Effect Log2(IC50(μM)) [95% CI]
ATRA TP53 wild-type vs mutant <0.001 0.0069 9.96 7.15 2.81 [1.82-3.79]
AZD6482 PIK3CA wild-type vs mutant <0.001 0.023 4.87 0.689 4.18 [2.73-5.63]
JNK Inhibitor VIII EGFR non-amplified vs. amplified <0.001 0.056 8.31 5.96 2.34 [1.49-3.20]
AZD6482 EGFR non-amplified vs. amplified <0.001 0.056 4.83 1.11 3.72 [2.17-5.26]
PF-562271 PIK3CA wild-type vs mutant <0.001 0.079 2.88 0.379 2.50 [1.55-3.46]
Legend: p – p value testing interaction, LFDR - local false discovery rate, WT - wild-type, NA - non-amplified, Mut – mutation, Amp – amplified, CI -
confidence interval.
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pan PI3K inhibitor GDC0941 (LFDR ≈ 1), which has a
markedly higher affinity for PI3Kα [24,25] indicating
that binding affinity may not be perfectly correlated
with in vitro activity, much less in vivo efficacy. As well,
compounds such as NVP-BEZ235, a PI3K/mTOR
inhibitor have been previously found to have selective
activity in PI3KCA-mutant HNSCC cell lines and
patient-derived xenografts (PDX) [26]. However, NVP-
BEZ235 activity did not correlate to PI3KCA mutant cell
lines in these studies, reinforcing the importance of
Figure 4 Drugs with differential activity by mutational status. (A) PI3K inhibitor AZD6482 demonstrates increased activity in PIK3CA mutant
versus wild-type cell lines. (B) When analysis was restricted to HNSCC cell lines, AZD6482 and FAK inhibitor PF-562271 demonstrated increased
activity in PIK3CA mutant lines. (C) AZD6482 and JNK Inhibitor VIII had increased activity in EGFR amplified cell lines relative to wild-type lines.
Points represent individual observations, while boxes show estimates of the respective median, interquartile range, and extrema.
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identifying the most promising preclinical candidates
that have the strongest correlation with genomic
changes to take forward into clinical trials.
There are two highly specific PI3Kα inhibitors, GDC-
0032 (Genetech) and BYL719 (Novartis) that have dem-
onstrated superior inhibition of PIK3CA mutant and
amplified cell lines as well as tumor xenografts [27,28].
Indeed, BYL719 was screened against the CCLE cell line
pool despite not being included in the report by Barre-
tina et al. [28]. Given these promising preclinical studies,
both compounds have been carried forward into phase I
trials, and the study for BYL719 has been completed
[27,28]. The trial included patients with solid tumors har-
boring PIK3CA amplifications and/or mutations including
8 HNSCC patients, six of which had stable disease and
two had partial responses (25%) [28]. A phase II study in
recurrent/metastatic HNSCC is already underway (http://
clinicaltrials.gov/ct2/show/NCT01602315). BYL719 is an
excellent example of a molecule initially identified in stud-
ies using cell lines, its efficacy confirmed in PDX models
and results of the first Phase I clinical trials are now in the
literature [29,30]. This process highlights the potential of
this “bench to bedside” approach using high throughput
platforms to identify effective anticancer agents. As tar-
geted therapy for cancer treatment continues to develop,
this bench to bedside approach will enable researchers to
screen large numbers of drugs against a multitude of can-
cer cell lines with the goal of confirming successful agents
in PDX models. Drugs that are found to be effective in
both cell lines and in mice combined with NGS for
biomarker prediction association, will better enable us to
accurately treat patients.
EGFR inhibitors have been integrated into routine
clinical care for HNSCC patients based on the landmark
Bonner study [31]. EGFR is the only targeted therapy
approved for the treatment of head and neck cancer.
Perhaps it is not surprising that two of the four EGFR
inhibitors that were tested demonstrated significantly
higher activity in HNSCC lines versus the rest of the cell
line pool (Table 1). However, only a subset of patients
benefit from these agents [15]. To better illustrate this,
Erlotinib was one of the EGFR inhibitors not found to
have significantly increased activity in HNSCC cell lines
compared with other cancer line types, further empha-
sizing the importance of accurate drug selection.
The mechanisms of sensitivity and resistance to EGFR
inhibitors in HNSCC are poorly understood [15]. In lung
cancer, EGFR response is tightly correlated with activat-
ing EGFR mutations, while resistance in colon cancer is
mediated by downstream KRAS mutations [15]. These
genetic changes essentially never occur in HNSCC [10],
and EGFR inhibitor response has not been correlated
with EGFR amplification or expression [15,31]. Indeed,
in our study we failed to identify a genetic correlate of
EGFR inhibitor sensitivity. An expanded study including
a larger number of molecularly characterized HNSCC
cell lines could potentially address this important clinical
issue.
While EGFR amplification was not correlated with
EGFR inhibitor efficacy, it was associated with increased
response to the PI3K inhibitor AZD6482 and JNK in-
hibitor VIII. EGFR signalling is mediated through several
pathways including PI3K and JNK [32,33]. As EGFR am-
plifications do occur in HNSCC [10], this potentially
relevant association should be explored further.
Ultimately our analysis is limited by the number of cell
lines, which restrict the number of lines with any given
genetic aberration(s) that could be tested. Another limi-
tation is that not all drugs were tested in all cell lines.
However, despite these limitations as well as discrepan-
cies in drug responses described by Papillon-Cavanagh
and colleagues [34], when comparing identical cell lines
that were screened against the same compounds in the
two studies, we found the results to be in agreement for
many of the cell lines (Additional file 5: Table S5). There
were 12 HNSCC cell lines displaying sensitivity to a
compound (IC50 below 8 μM) in either or both of the
studies. Of these 12 cases, ten were found to be very
similar between the two studies (IC50 values within
3 μM) (Additional file 5: Table S5). In cases where cell
lines displayed resistance, it was not possible for an exact
comparison to be performed since Barretina et al. only
screened drugs to a maximum of 8 μM, so many resistant
cell lines are merely listed as having an IC50 of 8 μM. In
contrast, Garnett et al. screened cell lines up to 3 orders
of magnitude higher (10 mM). However, if we compare
cell lines based on their characterization of resistance
(IC50 above 8 μM) in their respective study, we find that
the majority of cell line IC50 values were concordant be-
tween the two studies (Additional file 5: Table S5).
An additional limitation of our analysis is that all of
the cell lines utilized were HPV-negative to the best of
our knowledge [7]. Given the slow epidemic of HPV-
related oropharyngeal cancer, this is a glaring omission
as novel therapies for this patient cohort are of great
interest to the head and neck oncology community.
However, there are only 9 reported HPV-positive cell
lines in the literature, all of which were derived from ei-
ther recurrent tumors or smokers [35,36], and are thus
less likely to recapitulate the treatment-sensitive HPV-
positive tumors encountered in clinical practice. We sug-
gest that the development of further HPV-positive cell
lines and their incorporation into large-scale HNSCC cell
line drug screening studies has the potential to identify
novel effective agents and the mechanisms of drug sensi-
tivity and resistance in HNSCC. Hopefully, this will lead
to significant improvements in survival that has eluded us
to date.
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The disagreements noted in the cell line sensitivities
and mutations between the two studies have significant
implications for future work of this type. They are many
factors that can explain these discrepancies, however the
most likely is that the identically named lines are in fact
different, despite the fact that genotyping was completed
in both studies. Other possible sources of disagreements
in the data are differences in screening techniques, dif-
ferent drug concentrations, and different statistical
models to calculate IC50 values from the dose–response
curves. Ideally, the genotyping data can be compared to
determine the discrepancies and provide the definitive
genotype for cell lines. We also suggest that a standard
methodology of cell line drug screening needs to be de-
veloped to allow external validation of future findings.
Conclusions
High throughput drug screening of molecularly character-
ized HNSCC cell lines has the potential to rapidly identify
promising agents to improve therapies for patients suffer-
ing with head and neck cancer. An expanded HNSCC
specific study including HPV-positive cell lines has the po-
tential to identify effective agents, as well as mechanisms
of resistance and sensitivity to molecular agents.
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